Skeletal staging in Langerhans cell histiocytosis: a multimodality imaging review.
FDG PET-CT
Langerhans cell histiocytosis
Radiographic skeletal survey
Whole-body MRI
Whole-body bone scan
Journal
Skeletal radiology
ISSN: 1432-2161
Titre abrégé: Skeletal Radiol
Pays: Germany
ID NLM: 7701953
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
20
09
2020
accepted:
08
11
2020
revised:
29
10
2020
pubmed:
21
11
2020
medline:
25
6
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Evaluating the extent of skeletal disease in Langerhans cell histiocytosis (LCH) is a major predictor of patient outcome. Traditionally, whole-body skeletal staging consists of plain radiography and bone scintigraphy. However, more recently whole-body MRI has been shown to be accurate in detecting osseous and extra-osseous lesions, but no large-scale studies analysing its role within the diagnostic algorithm of LCH skeletal staging currently exist. In addition, FDG PET-CT provides useful information regarding disease activity and treatment response, but has an inherent radiation dose which is not ideal in children. Currently, radiographic skeletal survey remains the gold standard with cross-sectional imaging only performed for further characterisation. However, radiographs have shown a wide sensitivity range for skeletal staging and have clear limitations in detecting extra-skeletal disease, a crucial component of stratification in identifying 'at risk' organs. We aim to highlight the various appearances of bony LCH across all the imaging modalities for primary skeletal staging. We will also review the advantages, disadvantages, sensitivity and specificity of each, and establish their role in staging skeletal LCH. Recent studies using whole-body MRI have shown promising results, with radiographs and other modalities playing a more complementary role.
Identifiants
pubmed: 33215231
doi: 10.1007/s00256-020-03670-y
pii: 10.1007/s00256-020-03670-y
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1081-1093Références
WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. Lyon (France). International Agency for Research on Cancer; 2020. (WHO Classification of Tumours Series. 5
Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–31.
doi: 10.1182/blood.2019000934
Thacker NH, Abla O. Pediatric Langerhans cell histiocytosis: state of the science and future directions. Clin Adv Hematol Oncol. 2019;17(2):122–31.
pubmed: 30845115
Leung AKC, Lam JM, Leong KF. Childhood Langerhans cell histiocytosis: a disease with many faces. World J Pediatr. 2019;15(6):536–45.
doi: 10.1007/s12519-019-00304-9
Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018;109(12):3707–13.
doi: 10.1111/cas.13817
Arkader A, Glotzbecker M, Hosalkar HS, Dormans JP. Primary musculoskeletal Langerhans cell histiocytosis in children: an analysis for a 3-decade period. J Pediatr Orthop. 2009;29(2):201–7.
doi: 10.1097/BPO.0b013e3181982aa2
Kilpatrick SE, Wenger DE, Gilchrist GS, Shives TC, Wollan PC, Unni KK. Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer. 1995;76(12):2471–84.
doi: 10.1002/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z
Azouz EM, Saigal G, Rodriguez MM, Podda A. Langerhans’ cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2005;35(2):103–15.
doi: 10.1007/s00247-004-1262-0
LCH-IV iternational collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis. EudraCT Nr:2011–001699-20. Protocol Version 1.0, April 13th 2011.
Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156(6):873–881.e1.
doi: 10.1016/j.jpeds.2010.03.001
Jubran RF, Marachelian A, Dorey F, Malogolowkin M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005;45(1):37–42.
doi: 10.1002/pbc.20364
Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008;51(1):71–5.
doi: 10.1002/pbc.21498
Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008;25(3):291–5.
doi: 10.1111/j.1525-1470.2008.00669.x
Khung S, Budzik JF, Amzallag-Bellenger E, et al. Skeletal involvement in Langerhans cell histiocytosis. Insights Imaging. 2013;4(5):569–79.
doi: 10.1007/s13244-013-0271-7
Dogan AS, Conway JJ, Miller JH, Grier D, Bhattathiry MM, Mitchell CS. Detection of bone lesions in Langerhans cell histiocytosis: complementary roles of scintigraphy and conventional radiography. J Pediatr Hematol Oncol. 1996;18(1):51–8.
doi: 10.1097/00043426-199602000-00010
Howarth DM, Mullan BP, Wiseman GA, Wenger DE, Forstrom LA, Dunn WL. Bone scintigraphy evaluated in diagnosing and staging Langerhans’ cell histiocytosis and related disorders. J Nucl Med. 1996;37(9):1456–60.
pubmed: 8790192
Agarwal KK, Seth R, Behra A, Jana M, Kumar R. 18F-FluorodeoxyglucosePET/CT in Langerhans cell histiocytosis: spectrum of manifestations. Jpn J Radiol. 2016;34(4):267–76.
Gottumukkala RV, Gee MS, Hampilos PJ, Greer MC. Current and emerging roles of whole-body MRI in evaluation of pediatric cancer patients. Radiographics. 2019;39(2):516–34.
doi: 10.1148/rg.2019180130
Schäfer JF, Granata C, von Kalle T, et al. Whole-body magnetic resonance imaging in pediatric oncology - recommendations by the Oncology Task Force of the ESPR. Pediatr Radiol. 2020;50(8):1162–74.
doi: 10.1007/s00247-020-04683-4
Goo HW, Yang DH, Ra YS, et al. Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006;36(10):1019–31.
doi: 10.1007/s00247-006-0246-7
Steinborn M, Wörtler K, Nathrath M, Schöniger M, Hahn H, Rummeny EJ. Whole-body MRI in children with Langerhans cell histiocytosis for the evaluation of the skeletal system. Rofo. 2008;180(7):646–53.
doi: 10.1055/s-2008-1027345
Kim JR, Yoon HM, Jung AY, Cho YA, Seo JJ, Lee JS. Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep. 2019;9(1):317.
doi: 10.1038/s41598-018-36501-1
Singh J, Rajakulasingam R, Saifuddin A. Langerhans cell histiocytosis of the shoulder girdle, pelvis and extremities: a review of radiographic and MRI features in 85 cases [published online ahead of print, 2020 May 26]. Skelet Radiol. 2020;49(12):1925–37. https://doi.org/10.1007/s00256-020-03472-2 .
doi: 10.1007/s00256-020-03472-2
Parker BR, Pinckney L, Etcubanas E. Relative efficacy of radiographic and radionuclide bone surveys in the detection of the skeletal lesions of histiocytosis X. Radiology. 1980;134(2):377–80.
doi: 10.1148/radiology.134.2.6965429
Kumar R, Balachandran S. Relative roles of radionuclide scanning and radiographic imaging in eosinophilic granuloma. Clin Nucl Med. 1980;5(12):538–42.
doi: 10.1097/00003072-198012000-00002
Siddiqui AR, Tashjian JH, Lazarus K, Wellman HN, Baehner RL. Nuclear medicine studies in evaluation of skeletal lesions in children with histiocytosis X. Radiology. 1981;140(3):787–9.
doi: 10.1148/radiology.140.3.6456475
Crone-Münzebrock W, Brassow F. A comparison of radiographic and bone scan findings in histiocytosis X. Skelet Radiol. 1983;9(3):170–3.
doi: 10.1007/BF00352548
Westra SJ, van Woerden H, Postma A, Elema JD, Piers DA. Radionuclide bone scintigraphy in patients with histiocytosis X. Eur J Nucl Med. 1983;8(7):303–6.
doi: 10.1007/BF00253756
Schaub T, Ash JM, Gilday DL. Radionuclide imaging in histiocytosis X. Pediatr Radiol. 1987;17(5):397–404.
doi: 10.1007/BF02396617
Van Nieuwenhuyse JP, Clapuyt P, Malghem J, et al. Radiographic skeletal survey and radionuclide bone scan in Langerhans cell histiocytosis of bone. Pediatr Radiol. 1996;26(10):734–8.
doi: 10.1007/BF01383393
Girschikofsky M, Arico M, Castillo D, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis. 2013;8:72.
doi: 10.1186/1750-1172-8-72
Goyal G, Young JR, Koster MJMD, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. 2019;94(10):2054–71.
doi: 10.1016/j.mayocp.2019.02.023
Blum R, Seymour JF, Hicks RJ. Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma. 2002;43(11):2155–7.
doi: 10.1080/1042819021000032908
Kaste SC, Rodriguez-Galindo C, McCarville ME, Shulkin BL. PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Radiol. 2007;37(7):615–22.
doi: 10.1007/s00247-007-0467-4
Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009;52(1):97–101.
doi: 10.1002/pbc.21782
Lee HJ, Ahn BC, Lee SW, Lee J. The usefulness of F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Langerhans cell histiocytosis. Ann Nucl Med. 2012;26(9):730–7.
doi: 10.1007/s12149-012-0635-y
Mueller WP, Melzer HI, Schmid I, Coppenrath E, Bartenstein P, Pfluger T. The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis. Eur J Nucl Med Mol Imaging. 2013;40(3):356–63.
doi: 10.1007/s00259-012-2278-6
Zhou W, Wu H, Han Y, Wang S, Dong Y, Wang Q. Preliminary study on the evaluation of Langerhans cell histiocytosis using F-18-fluoro-deoxy-glucose PET/CT. Chin Med J. 2014;127(13):2458–62.
pubmed: 24985583
Albano D, Bosio G, Giubbini R, Bertagna F. Role of
doi: 10.1007/s11604-017-0668-1
Jessop S, Crudgington D, London K, Kellie S, Howman-Giles R. FDG PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer. 2020;67(1):e28034.
doi: 10.1002/pbc.28034
Obert J, Vercellino L, Van Der Gucht A, et al.
doi: 10.1007/s00259-016-3521-3
Wu M, Niu N, Huo L. Clinical utility of
doi: 10.2967/jnumed.120.249219
Nakamura N, Inaba Y, Aota Y, Machida J, Saito T. Characteristic reconstitution of the spinal Langerhans cell histiocytosis in young children. J Pediatr Orthop. 2019;39(4):e308–11.
doi: 10.1097/BPO.0000000000001283
Huang B, Law MW, Khong PL. Whole-bodyPET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251(1):166–74.
Kalus S, Saifuddin A. Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: a 12-year single-institution review. Eur Radiol. 2019;29(10):5700–8.
doi: 10.1007/s00330-019-06132-9
Preez HD, Lasker I, Rajakulasingam R, Saifuddin A. Whole-body magnetic resonance imaging: incidental findings in paediatric and adult populations [published online ahead of print, 2020 Jun 30]. Eur J Radiol. 2020;130:109156. https://doi.org/10.1016/j.ejrad.2020.109156 .
doi: 10.1016/j.ejrad.2020.109156
pubmed: 32645680